Product Program year 2025 Source: CMS Open Payments

Orbactiv

Drug Antibiotics

NDC 70842-140-03

Open in the dashboard

General payments

$1,096,953

20,899 payments

Research payments

$1,189,201

210 payments

Through program year 2025, $1,096,953 in general payments and $1,189,201 in research payments were reported against Orbactiv (Antibiotics).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $107,964 1,999
2025 Research $47,014 28
2024 General $94,925 1,931
2024 Research $139,105 47
2023 General $99,211 2,046
2023 Research $265,274 36
2022 General $285,879 3,449
2022 Research $21,104 23
2021 General $140,983 3,940
2021 Research $21,996 13
2020 General $106,150 2,408
2020 Research $51,395 20
2019 General $261,842 5,126
2019 Research $643,314 43

Breakdown

Who paid General payments · program years 2019–2025
  1. Melinta Therapeutics, Inc. $1,096,953 20,899 payments
Top recipients General payments · program year 2025
  1. Matthew Wikler Infectious Disease · San Diego, CA $38,924 36% · 12 payments
  2. University Hospital Teaching hospital · KY $7,000 6% · 3 payments
  3. Henry Ford Hospital Teaching hospital · MI $7,000 6% · 3 payments
  4. Strong Memorial Hospital Teaching hospital · NY $3,820 4% · 1 payment
  5. John Bradley Pediatric Infectious Diseases · San Diego, CA $3,000 3% · 2 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Infectious Disease Internal Medicine $54,972 64% · 278 practitioners
  2. Pediatric Infectious Diseases Pediatrics $6,680 8% · 4 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $4,398 5% · 93 practitioners
  4. Internal Medicine $3,206 4% · 93 practitioners
  5. Physician Assistant $2,701 3% · 63 practitioners

The top 5 of 55 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $43,133 40% · 26 recipients
  2. New York $10,331 10% · 119 recipients
  3. Kentucky $9,453 9% · 28 recipients
  4. Michigan $7,382 7% · 9 recipients
  5. Florida $5,431 5% · 86 recipients

The top 5 of 39 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to Orbactiv
Billing code Providers Services Paid by Medicare
Injection, oritavancin, 10 mg J2407 3 7,320 $157,375

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

20,899 general · 210 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record